| 2.46 Delayed Data As of Apr 18 |  -0.07 / -2.77%Today’s Change | 2.27 Today|||52-Week Range 12.31 | -48.75% Year-to-Date |
| Here's Why ImmunoGen Tumbled 43% in March Apr 08 / MotleyFool.com - Paid Partner Content |
| Previous close | 2.53 |
| Today’s open | 2.53 |
| Day’s range | 2.41 - 2.57 |
| Volume | 3,143,382 |
| Average volume (3 months) | 3,278,906 |
| Market cap | $874.0M |
| Earnings growth (last year) | -23.11% |
| Earnings growth (this year) | +9.33% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -53.71% |
| P/E ratio | NM |
| Price/Sales | 12.57 |
| Price/Book | 79.66 |
| Today’s change | Today’s % change | |
|---|---|---|
| KZRKezar Life Sciences ... | -0.77 | -3.85% |
| MRUSMerus NV | +0.55 | +3.63% |
| ADVMAdverum Biotechnolog... | +0.33 | +5.84% |
| UBXUnity Biotechnology ... | +0.16 | +2.04% |
| Next reporting date | May 3, 2019 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $53.4M |
| Annual profit (last year) | -$168.8M |
| Net profit margin | -315.91% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer, CFO & Director Mark J. Enyedy |
Chief Scientific Officer & EVP-Research Richard J. Gregory |
Corporate headquarters Waltham, Massachusetts |
